BiO2 Medical pulls in $12M to market catheter

BiO2 Medical's Angel catheter is designed to prevent pulmonary embolism--courtesy of BiO2 Medical

San Antonio-based devicemaker BiO2 Medical snagged $12 million in a Series C round, money the company will use to commercialize its Angel catheter.

Remeditex Ventures led the round, joined by BiO2's previous investors, including Incyte Ventures Targeted Technology Fund and Pasadera Capital. The company closed a $13.7 million Series B earlier this year. 

Angel, named for BiO2 founder Dr. Luis Angel, is a central venous catheter and inferior vena cava filter combination device, designed to prevent pulmonary embolism in critically ill patients.

BiO2 says Angel is the first catheter of its kind to function as an inferior vena cava filter, and the tech will help venous thrombosis patients for whom anticoagulation therapy poses a high risk of complications.

John Creecy, Remidex's CEO, said BiO2 has a promising product that addresses a huge unmet need. "We believe the company is poised to become an important innovator, addressing the needs of patients by substantially reducing the risks associated with pulmonary embolism," Creecy said in a statement.

BiO2 has applied for CE mark for Angel and is targeting FDA approval in the future. The company has started a first-in-human clinical study of the device in Medellín, Colombia.

- read BiO2's release

Suggested Articles

Takeda tapped Roche’s Foundation Medicine to develop tissue- and blood-based companion diagnostic tests for its portfolio of lung cancer therapies.

Cellex has announced plans to develop a rapid coronavirus test that people can fully perform at home, from sample collection to result, using an app.

More than 20 states either don’t release or have incomplete data on the rapid antigen tests now considered key to containing the coronavirus.